TIM-3 is relatively higher expressed on leukemic stem cells than non-neoplastic hematopoietic stem cells, often in conjunction with other surface antigens such as CD33, CD123, and CLL, thus targeting TIM3 might be a novel approach in cancer treatment in the future [103]. The gene discussed is HAVCR2; the disease is B-cell chronic lymphocytic leukemia.